|
First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B. |
|
|
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma |
Research Funding - Bristol-Myers Squibb; Prometheus (Inst) |
|
|
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Pfizer; Sanofi/Aventis |
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche/Genentech |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre |
|
Rustem Airatovich Gafanov |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Ipsen; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Genzyme; Janssen; Sanofi |
|
Travel, Accommodations, Expenses - Abbvie; Astellas Pharma (I); Bayer; Genzyme; Janssen; Sanofi |
|
|
Research Funding - Astellas Pharma; AstraZeneca; Janssen; Merck; Roche |
|
|
Honoraria - Astellas Pharma; Ipsen; Pfizer |
Consulting or Advisory Role - Astellas Pharma; Ipsen; Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Pfizer |
|
|
No Relationships to Disclose |
|
Miguel Angel Climent Duran |
Honoraria - Bristol-Myers Squibb; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma |